Patents by Inventor Craig A. Harrison

Craig A. Harrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cripto antagonism of activin and TGF-b signaling
    Patent number: 9546210
    Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: January 17, 2017
    Assignee: Research Development Foundation
    Inventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
  • CRIPTO ANTAGONISM OF ACTIVIN AND TGF-B SIGNALING
    Publication number: 20120141469
    Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.
    Type: Application
    Filed: October 19, 2011
    Publication date: June 7, 2012
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
  • CRIPTO ANTAGONISM OF ACTIVIN AND TGF-B SIGNALING
    Publication number: 20120088287
    Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.
    Type: Application
    Filed: October 19, 2011
    Publication date: April 12, 2012
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
  • CRIPTO ANTAGONISM OF ACTIVIN AND TGF-B SIGNALING
    Publication number: 20110009319
    Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.
    Type: Application
    Filed: September 21, 2010
    Publication date: January 13, 2011
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
  • Cripto antagonism of activin and TGF-b signaling
    Patent number: 7820620
    Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: October 26, 2010
    Assignee: Research Development Foundation
    Inventors: Wylie Vale, Craig A. Harrison, Peter C. Gray